JNJ vs. LLY, ABBV, MRK, PFE, BMY, NVO, AZN, NVS, ABT, and SNY
Should you be buying Johnson & Johnson stock or one of its competitors? The main competitors of Johnson & Johnson include Eli Lilly and (LLY), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol-Myers Squibb (BMY), Novo Nordisk A/S (NVO), AstraZeneca (AZN), Novartis (NVS), Abbott Laboratories (ABT), and Sanofi (SNY). These companies are all part of the "pharmaceutical preparations" industry.
Johnson & Johnson vs.
Eli Lilly and (NYSE:LLY) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.
Eli Lilly and has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500.
Johnson & Johnson has higher revenue and earnings than Eli Lilly and. Johnson & Johnson is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.
Eli Lilly and has a net margin of 21.88% compared to Johnson & Johnson's net margin of 18.90%. Eli Lilly and's return on equity of 73.61% beat Johnson & Johnson's return on equity.
82.1% of Eli Lilly and shares are held by institutional investors. Comparatively, 67.9% of Johnson & Johnson shares are held by institutional investors. 0.1% of Eli Lilly and shares are held by insiders. Comparatively, 0.4% of Johnson & Johnson shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Eli Lilly and received 75 more outperform votes than Johnson & Johnson when rated by MarketBeat users. Likewise, 71.21% of users gave Eli Lilly and an outperform vote while only 65.15% of users gave Johnson & Johnson an outperform vote.
Eli Lilly and pays an annual dividend of $4.52 per share and has a dividend yield of 1.3%. Johnson & Johnson pays an annual dividend of $4.52 per share and has a dividend yield of 3.0%. Eli Lilly and pays out 65.5% of its earnings in the form of a dividend. Johnson & Johnson pays out 67.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Eli Lilly and has increased its dividend for 9 consecutive years and Johnson & Johnson has increased its dividend for 61 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
Eli Lilly and currently has a consensus target price of $382.05, suggesting a potential upside of 13.66%. Johnson & Johnson has a consensus target price of $174.73, suggesting a potential upside of 14.47%. Given Johnson & Johnson's higher possible upside, analysts clearly believe Johnson & Johnson is more favorable than Eli Lilly and.
In the previous week, Eli Lilly and had 8 more articles in the media than Johnson & Johnson. MarketBeat recorded 25 mentions for Eli Lilly and and 17 mentions for Johnson & Johnson. Johnson & Johnson's average media sentiment score of 0.63 beat Eli Lilly and's score of 0.58 indicating that Johnson & Johnson is being referred to more favorably in the news media.
Summary
Eli Lilly and beats Johnson & Johnson on 13 of the 21 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding JNJ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Johnson & Johnson Competitors List
